Advertisement

CDC Issues Updated Recommendations for VariZIG — Physician’s First Watch

Medical News |
July 19, 2013

CDC Issues Updated Recommendations for VariZIG

By Amy Orciari Herman

The CDC has issued updated recommendations for the use of VariZIG, the varicella-zoster immunoglobulin given for postexposure prophylaxis in high-risk patients and for whom the varicella vaccine is contraindicated.

As reported in MMWR, the CDC has extended the treatment window for VariZIG to 10 days (instead of 4) after exposure to varicella zoster — although the earlier, the better. In addition, the period of eligibility for use in premature infants has been extended to include exposures that occur throughout the length of hospitalization for prematurity.

VariZIG is recommended for the following groups: immunocompromised patients without apparent immunity; newborns whose mothers have signs of varicella in the peripartum period; hospitalized premature infants born at 28 weeks or later whose mothers don't have evidence of immunity, or those born before 28 weeks, regardless of their mothers' immunity status; and pregnant women without immunity.

VariZIG is available from one U.S. distributor, FFF Enterprises.

Reader Comments (1)

ABDULLAH ALGARNI Fellow-In-Training, Infectious Disease, military hospital in KSARIYAD

very nice summary

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement